ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Revolutionizing Trial Supply Management With The Power Of Free Picking

  Discover the power of SmartSignals RTSM’s new free picking feature, designed to revolutionize trial supply management by optimizing efficiency and reducing costs.

• FDA Pushes For Patient Voice: ePRO In Oncology Trials

  FDA urges sponsors and CROs to include patient voices in oncology trials. Discover why it matters and how to start integrating this approach.

• Customizing EDC Workflows For Specialty Pharma, Rare Disease Trials

  Rare disease and specialty pharma trials demand a level of flexibility with electronic data capture systems that can adapt dynamically without sacrificing data integrity.

• Innovation And Architecture That Delivers Simplicity And Customizability

  Whether you're looking for no-code simplicity, low-code adaptability, or fully programmable control, this purpose-built technology platform supports trials of all complexities with ease.

• Real-World Data Vs. Real-World Evidence

  Unearth the ways real-world data (RWD) and real-world evidence (RWE) in clinical R&D can be used to provide additional validation for new therapies and drugs regarding their efficacy, safety, and value.

• The False Economy Of Paper Diaries In Clinical Trials

  While paper diaries may appear cheaper, but there are hidden costs that make a digital eCOA solution much more affordable in your clinical trial.

• Medical Device Clinical Trials: Key Considerations For Sponsors And CROs

  Medical device trials must align risk class, regulations, and study design. Strong oversight, data, and proactive safety planning support reliable evidence and market approval.

• 6 Key Ways Real-World Data Is Advancing Colorectal Cancer Therapies

  Real-world data (RWD) is transforming colorectal cancer (CRC) research by complementing traditional clinical trials, accelerating drug development, and improving patient outcomes.

• Opportunities For Enhancing Signal Detection In Schizophrenia Trials

  Signal detection in schizophrenia trials is hindered by increased placebo response, complex rating scales, inconsistent rater performance, and data quality issues.

• The Hidden Cost Of Preferred Vendors

  Familiar vendors offer comfort — but at the cost of innovation, fit, and fresh thinking. Ease shouldn’t outweigh excellence when selecting partners for your clinical trial.